Revolutionizing Biomedical Implants in 2025: How Suspension Plasma Spraying is Shaping the Next Era of Advanced Coatings and Market Growth. Explore the Breakthroughs, Key Players, and Forecasts Driving This High-Impact Sector.

Executive Summary: 2025 Market Overview and Key Insights
Technology Primer: Fundamentals of Suspension Plasma Spraying (SPS)
Biomedical Implant Applications: Current and Emerging Use Cases
Competitive Landscape: Leading Companies and Innovators (e.g., oerlikon.com, lincotekmedical.com)
Market Size and Growth Forecast (2025–2030): CAGR, Revenue, and Volume Projections
Material Science Advances: Bioactive and Multifunctional Coatings
Regulatory and Quality Standards: ISO, FDA, and Industry Guidelines (e.g., fda.gov, iso.org)
Challenges and Barriers: Technical, Economic, and Clinical Adoption
Strategic Partnerships and R&D Initiatives (e.g., ieee.org, asme.org)
Future Outlook: Disruptive Trends, Investment Hotspots, and Long-Term Opportunities
Sources & References

Executive Summary: 2025 Market Overview and Key Insights

Suspension Plasma Spraying (SPS) is rapidly emerging as a transformative surface engineering technology in the biomedical implant sector, with 2025 marking a pivotal year for its commercial and clinical adoption. SPS enables the deposition of ultra-fine, nanostructured coatings—most notably hydroxyapatite (HA) and other bioactive ceramics—onto metallic implant substrates, enhancing osseointegration, wear resistance, and long-term biocompatibility. The technology’s ability to tailor surface morphology and chemistry at the micro- and nanoscale is driving its uptake in orthopedics, dental, and spinal implant applications.

In 2025, the SPS market for biomedical implants is characterized by a convergence of technological maturation, regulatory progress, and increased investment from leading implant manufacturers. Companies such as TST GmbH and Oerlikon are at the forefront, offering advanced SPS equipment and coating services tailored for medical device applications. Oerlikon, in particular, has expanded its portfolio to include SPS-applied bioactive coatings, leveraging its global presence and established relationships with orthopedic OEMs. Meanwhile, TST GmbH continues to innovate in plasma spray process control and suspension formulation, supporting the customization of implant surfaces for specific clinical needs.

Recent data from industry sources and regulatory filings indicate a steady increase in the number of SPS-coated implants entering preclinical and clinical evaluation phases. The European Union’s Medical Device Regulation (MDR) and the U.S. Food and Drug Administration’s (FDA) evolving guidance on nanostructured coatings are shaping the pace of market entry, with several SPS-coated products anticipated to receive CE marking or FDA clearance by late 2025 or early 2026. This regulatory momentum is expected to accelerate the adoption of SPS in next-generation hip, knee, and dental implants.

Key insights for 2025 include a growing emphasis on the reproducibility and scalability of SPS processes, as manufacturers seek to meet stringent quality standards and rising demand. Strategic collaborations between coating technology providers and implant OEMs are intensifying, with joint development agreements and technology licensing becoming more common. Additionally, the integration of digital process monitoring and AI-driven quality control is beginning to reshape production workflows, further enhancing the reliability of SPS coatings.

Looking ahead, the outlook for SPS in biomedical implants is robust. The technology is poised to capture a significant share of the advanced implant coatings market over the next few years, driven by its unique ability to deliver functionalized, durable, and patient-specific surfaces. As clinical evidence mounts and regulatory pathways clarify, SPS is set to become a standard in the design and manufacture of high-performance biomedical implants.

Technology Primer: Fundamentals of Suspension Plasma Spraying (SPS)

Suspension Plasma Spraying (SPS) is an advanced thermal spray technique that has gained significant traction in the biomedical implant sector, particularly for the deposition of bioactive and functional coatings. Unlike conventional plasma spraying, which uses powder feedstock, SPS utilizes a liquid suspension containing fine ceramic or composite particles. This enables the creation of coatings with unique microstructures, such as nanostructured or highly porous layers, which are highly desirable for biomedical applications.

The SPS process involves injecting the suspension into a high-temperature plasma jet, where the liquid rapidly evaporates, and the solid particles are accelerated toward the substrate. The resulting coatings can be tailored for specific properties, such as enhanced osseointegration, antimicrobial activity, or controlled drug release. In 2025, SPS is being increasingly adopted for coating orthopedic and dental implants with materials like hydroxyapatite (HA), titanium dioxide, and bioactive glass, aiming to improve implant longevity and patient outcomes.

Key industry players are actively developing and supplying SPS equipment and materials. Oerlikon, a global leader in surface solutions, offers advanced plasma spray systems and has highlighted SPS as a strategic technology for biomedical coatings. Their systems are designed for precise control of process parameters, enabling reproducible and high-quality coatings. TST Coatings, a specialist in thermal spray technologies, also provides SPS services for medical device manufacturers, focusing on customized solutions for implant surfaces.

The versatility of SPS allows for the deposition of multilayer and gradient coatings, which are increasingly in demand for next-generation implants. For example, coatings with a dense inner layer for mechanical stability and a porous outer layer for bone ingrowth are being explored. The ability to incorporate nanoparticles or therapeutic agents into the suspension further expands the functional possibilities of SPS coatings.

Industry organizations such as the ASM International and the Thermal Spray Society are actively promoting knowledge exchange and standardization efforts for SPS in biomedical applications. These bodies facilitate collaboration between equipment manufacturers, medical device companies, and research institutions to accelerate the adoption of SPS.

Looking ahead, the outlook for SPS in biomedical implants is robust. Ongoing research and industrial investment are expected to drive further improvements in coating performance, process scalability, and regulatory acceptance. As the demand for advanced implant surfaces grows, SPS is poised to play a pivotal role in the development of safer, longer-lasting, and more functional biomedical devices through 2025 and beyond.

Biomedical Implant Applications: Current and Emerging Use Cases

Suspension Plasma Spraying (SPS) is rapidly gaining traction as a transformative surface engineering technology for biomedical implants, particularly in orthopedics and dental applications. As of 2025, SPS is being leveraged to deposit ultra-fine, nanostructured coatings—most notably hydroxyapatite (HA) and other bioactive ceramics—onto metallic implant substrates. This approach addresses critical challenges in implantology, such as improving osseointegration, enhancing corrosion resistance, and tailoring surface topography for optimal cellular response.

Recent years have seen a shift from conventional plasma spraying to SPS due to its ability to process submicron and nanoscale suspensions, resulting in coatings with higher surface area, controlled porosity, and improved mechanical properties. These features are particularly advantageous for next-generation implants, where the interface between the implant and biological tissue is crucial for long-term success. Companies such as Oerlikon and TST Coatings are actively developing and offering SPS solutions for medical device manufacturers, focusing on HA and composite coatings that mimic the natural bone environment.

In 2025, SPS is being applied to titanium and titanium alloy implants to create bioactive surfaces that promote rapid bone in-growth. The technology allows for precise control over coating thickness (often in the 10–100 μm range) and microstructure, enabling the fabrication of gradient or multilayer coatings that combine bioactivity with wear and corrosion resistance. This is particularly relevant for load-bearing implants such as hip and knee replacements, as well as dental implants, where early fixation and long-term stability are paramount.

Emerging use cases include the deposition of antibacterial and drug-eluting coatings, where SPS enables the incorporation of therapeutic agents or silver nanoparticles into the ceramic matrix. This is being explored to reduce post-surgical infection rates and improve patient outcomes. Additionally, research and pilot-scale production are underway for coatings that combine HA with other bioactive phases (e.g., tricalcium phosphate, bioactive glass) to further enhance biological performance.

Looking ahead, the outlook for SPS in biomedical implants is robust. Industry leaders such as Oerlikon are investing in process automation and quality control to meet stringent regulatory requirements and scale up production. The next few years are expected to see broader clinical adoption, especially as SPS-coated implants demonstrate superior integration and longevity in preclinical and early clinical studies. As regulatory pathways become clearer and more device manufacturers adopt SPS, the technology is poised to become a standard for advanced implant surface modification.

Competitive Landscape: Leading Companies and Innovators (e.g., oerlikon.com, lincotekmedical.com)

The competitive landscape for Suspension Plasma Spraying (SPS) in biomedical implants is rapidly evolving as the demand for advanced surface coatings grows in orthopedics, dental, and trauma applications. As of 2025, several established players and innovative newcomers are shaping the market, leveraging SPS to deliver superior bioactive and nanostructured coatings that enhance osseointegration, wear resistance, and implant longevity.

Among the global leaders, Oerlikon stands out with its Surface Solutions division, which has invested heavily in plasma spray technologies, including SPS. Oerlikon’s expertise in thermal spray processes and its global network of production and R&D facilities position it as a key supplier to major orthopedic implant manufacturers. The company’s focus on process control and reproducibility is critical for meeting stringent medical device regulations.

Another major player is Lincotek Medical, a vertically integrated contract manufacturer specializing in surface treatments for medical implants. Lincotek Medical has expanded its plasma spray capabilities to include SPS, offering customized hydroxyapatite and titanium coatings for hip, knee, and dental implants. The company’s global footprint, with manufacturing sites in Europe, North America, and Asia, enables it to serve leading OEMs and adapt to regional regulatory requirements.

In addition to these giants, specialized coating providers such as Bodycote are also active in the SPS space. Bodycote, known for its thermal processing services, has incorporated advanced plasma spray techniques to address the growing need for bioactive and antimicrobial coatings in the medical sector. Their focus on quality assurance and traceability aligns with the increasing scrutiny from regulatory bodies.

Emerging innovators are also making their mark. Companies like Flame Spray are developing proprietary SPS processes to produce nanostructured coatings with enhanced biological performance. These firms often collaborate with academic institutions and implant manufacturers to accelerate the translation of laboratory advances into commercial products.

Looking ahead, the competitive landscape is expected to intensify as SPS technology matures and regulatory pathways become clearer. Companies are investing in automation, in-line quality monitoring, and digital process control to ensure consistency and scalability. Strategic partnerships between coating specialists, implant OEMs, and research organizations are likely to drive further innovation, particularly in the development of multifunctional coatings that combine bioactivity with antimicrobial or drug-eluting properties. As SPS adoption grows, the market will favor those companies that can deliver validated, reproducible, and regulatory-compliant solutions at scale.

Market Size and Growth Forecast (2025–2030): CAGR, Revenue, and Volume Projections

The global market for Suspension Plasma Spraying (SPS) in biomedical implants is poised for robust growth between 2025 and 2030, driven by increasing demand for advanced surface coatings that enhance implant performance, biocompatibility, and longevity. SPS technology, which enables the deposition of finely structured, nanostructured, or multi-functional coatings, is gaining traction as a preferred method for orthopedic, dental, and other medical implants.

Current estimates suggest that the SPS segment within the broader biomedical coatings market will experience a compound annual growth rate (CAGR) of approximately 8–11% from 2025 to 2030. This growth is underpinned by rising surgical volumes, an aging global population, and the need for implants with improved osseointegration and wear resistance. The total revenue generated by SPS-applied biomedical coatings is projected to reach several hundred million USD by 2030, with annual volumes expected to increase in tandem as more manufacturers adopt SPS for next-generation implant products.

Key industry players such as Oerlikon and Bodycote are actively expanding their SPS capabilities, investing in new equipment and R&D to meet the growing demand for high-performance coatings. Oerlikon, a global leader in surface solutions, has reported increased interest from medical device manufacturers seeking SPS for hydroxyapatite and other bioactive coatings, which are critical for bone integration and implant stability. Similarly, Bodycote is leveraging its expertise in thermal spray technologies to offer SPS solutions tailored to the stringent requirements of the medical sector.

The adoption of SPS is also being facilitated by advancements in suspension formulation, process control, and in-line quality monitoring, which are reducing costs and improving reproducibility. Organizations such as TST Coatings and Hauzer Techno Coating are contributing to the market by providing contract coating services and turnkey SPS systems, enabling both established and emerging implant manufacturers to access this technology without significant capital investment.

Looking ahead, the SPS market for biomedical implants is expected to benefit from regulatory approvals of new coated products, ongoing clinical validation, and the trend toward personalized medicine. As SPS becomes more widely adopted, the market is likely to see further consolidation among coating service providers and equipment manufacturers, as well as increased collaboration with medical device OEMs. Overall, the outlook for SPS in biomedical implants from 2025 to 2030 is one of sustained double-digit growth, technological innovation, and expanding clinical applications.

Material Science Advances: Bioactive and Multifunctional Coatings

Suspension plasma spraying (SPS) is rapidly emerging as a transformative technology in the field of biomedical implants, particularly for the development of bioactive and multifunctional coatings. As of 2025, SPS is being leveraged to address the growing demand for advanced surface modifications that enhance osseointegration, antimicrobial performance, and long-term stability of orthopedic and dental implants.

SPS distinguishes itself from conventional plasma spraying by utilizing fine ceramic or composite particles suspended in a liquid, enabling the deposition of coatings with submicron and nanostructured features. This results in surfaces with higher specific surface area, tailored porosity, and improved mechanical interlocking with bone tissue. Recent years have seen a surge in research and pilot-scale production of SPS-applied hydroxyapatite (HA), titanium dioxide, and bioactive glass coatings, which are known to promote bone cell attachment and proliferation.

Key industry players are actively advancing SPS technology for biomedical applications. Oerlikon, a global leader in surface solutions, has expanded its portfolio to include SPS systems and process development for medical device manufacturers. Their efforts focus on optimizing coating homogeneity and adhesion, critical for the longevity and safety of implants. Similarly, TST Coatings is collaborating with implant producers to tailor SPS coatings for specific clinical needs, such as enhanced wear resistance and controlled drug release.

In 2025, the integration of bioactive agents—such as silver nanoparticles for antimicrobial action or growth factors for accelerated healing—into SPS coatings is gaining traction. This multifunctional approach is being explored in partnership with implant manufacturers and research institutions, aiming to reduce infection rates and improve patient outcomes. For example, TST Coatings has reported successful pilot studies on SPS-applied antimicrobial coatings for titanium implants, with promising in vitro and early in vivo results.

Regulatory pathways for SPS-coated implants are also evolving. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are engaging with industry stakeholders to establish standards for nanostructured and multifunctional coatings, reflecting the increasing clinical interest and anticipated market entry of SPS-enabled products in the next few years.

Looking ahead, the outlook for SPS in biomedical implants is robust. Ongoing collaborations between coating technology providers, implant manufacturers, and clinical researchers are expected to accelerate the translation of SPS coatings from laboratory to commercial products. The next few years will likely see the first SPS-coated implants entering clinical trials and, subsequently, the market, driven by the need for improved implant longevity, reduced complications, and enhanced patient quality of life.

Regulatory and Quality Standards: ISO, FDA, and Industry Guidelines (e.g., fda.gov, iso.org)

Suspension Plasma Spraying (SPS) is gaining traction as a surface engineering technique for biomedical implants, offering the ability to deposit finely structured, bioactive coatings such as hydroxyapatite and other ceramics. As of 2025, the regulatory and quality landscape for SPS-applied coatings is evolving, with increasing attention from both international standards organizations and national regulatory bodies.

The International Organization for Standardization (ISO) remains central to the regulation of medical device coatings. ISO 13779-2:2018, which specifies requirements for hydroxyapatite coatings on metallic implants, is widely referenced. While this standard does not yet explicitly mention SPS, its criteria for phase composition, crystallinity, and adhesion are directly relevant. Ongoing discussions within ISO technical committees are expected to address the unique features of SPS, such as its ability to produce nanostructured and multi-phase coatings, in future revisions.

In the United States, the U.S. Food and Drug Administration (FDA) regulates medical devices under the 21 CFR Part 820 Quality System Regulation. For implants with plasma-sprayed coatings, the FDA requires detailed characterization of coating composition, thickness, adhesion, and potential impurities. The FDA’s guidance for industry on “Hydroxyapatite Coatings for Orthopedic and Dental Implants” (updated in 2024) now explicitly encourages manufacturers to provide data on novel plasma spray techniques, including SPS, particularly regarding coating uniformity and long-term stability. The FDA also expects biocompatibility testing in accordance with ISO 10993, and is increasingly scrutinizing the potential for nanoparticle release from SPS coatings.

Industry groups such as the ASTM International are also active in this space. ASTM F1185 and F1147, which cover hydroxyapatite coatings and adhesion testing, respectively, are being reviewed to better accommodate the finer microstructures and unique properties of SPS coatings. Leading implant manufacturers, including Zimmer Biomet and Smith+Nephew, are participating in these standardization efforts, as they explore SPS for next-generation orthopedic and dental implants.

Looking ahead, regulatory agencies are expected to issue more specific guidance for SPS, particularly as clinical data accumulates and as more manufacturers seek premarket approval for SPS-coated devices. The next few years will likely see the publication of new ISO and ASTM standards tailored to SPS, as well as increased harmonization between U.S., European, and Asian regulatory frameworks. This evolving landscape will require manufacturers to maintain robust quality management systems and to stay abreast of changing requirements to ensure compliance and market access.

Challenges and Barriers: Technical, Economic, and Clinical Adoption

Suspension Plasma Spraying (SPS) is gaining attention as a promising surface engineering technique for biomedical implants, offering the ability to deposit finely structured, bioactive coatings. However, as of 2025, several challenges and barriers continue to impede its widespread technical, economic, and clinical adoption.

Technical Challenges

Process Control and Reproducibility: SPS involves the injection of submicron or nanosized particles suspended in a liquid into a plasma jet. Achieving consistent coating microstructure and properties remains difficult due to the complex interplay of suspension formulation, plasma parameters, and substrate conditions. Leading plasma equipment manufacturers such as Oerlikon and Thermal Spray Technologies are actively developing advanced process monitoring and control systems, but real-time feedback and closed-loop control are still in early stages for SPS.
Material Limitations: While SPS enables the use of a broader range of materials (e.g., hydroxyapatite, bioglass), the stability of suspensions and the risk of phase decomposition during spraying are ongoing concerns. Companies like Thermal Spray Technologies are working on optimized feedstock formulations, but standardization is lacking.

Economic Barriers

High Initial Investment: SPS systems require specialized hardware, including high-precision injectors and advanced plasma torches, leading to higher capital costs compared to conventional plasma spraying. This is a significant barrier for smaller implant manufacturers.
Production Throughput: The relatively slow deposition rates and the need for post-processing (e.g., heat treatment) can limit scalability. While companies such as Oerlikon are developing automated solutions, cost-effective high-volume production remains a challenge.

Clinical Adoption and Regulatory Hurdles

Long-Term Clinical Data: Regulatory bodies require extensive in vivo and clinical data to approve new implant coatings. As SPS is a relatively new technology in the biomedical sector, long-term safety and efficacy data are limited, slowing regulatory approval and clinical uptake.
Standardization and Certification: There is a lack of harmonized standards for SPS coatings on implants. Industry groups and standards organizations are only beginning to address this gap, which complicates certification and market entry.

Outlook (2025 and Beyond)

Over the next few years, ongoing R&D by major plasma technology providers and implant manufacturers is expected to address some technical and economic barriers. However, clinical adoption will likely remain gradual until robust long-term data and standardized protocols are established. Collaboration between industry leaders such as Oerlikon, Thermal Spray Technologies, and regulatory bodies will be crucial for broader adoption of SPS in biomedical implants.

Strategic Partnerships and R&D Initiatives (e.g., ieee.org, asme.org)

Strategic partnerships and research and development (R&D) initiatives are playing a pivotal role in advancing suspension plasma spraying (SPS) for biomedical implants as of 2025. The SPS technique, which enables the deposition of finely structured, bioactive coatings on implant surfaces, is increasingly recognized for its potential to improve osseointegration and long-term implant performance. This has spurred collaborations among academic institutions, industry leaders, and standards organizations to accelerate innovation and commercialization.

A notable trend in 2025 is the formation of consortia and joint ventures between medical device manufacturers and plasma technology specialists. For example, companies such as Oerlikon, a global leader in surface solutions, have established partnerships with universities and research hospitals to optimize SPS parameters for hydroxyapatite and other bioactive coatings. These collaborations focus on tailoring coating microstructures to enhance cell adhesion and reduce the risk of implant rejection.

Industry bodies like the American Society of Mechanical Engineers (ASME) and the Institute of Electrical and Electronics Engineers (IEEE) are actively supporting the development of standards and best practices for SPS in biomedical applications. In 2025, working groups within these organizations are addressing critical issues such as coating uniformity, reproducibility, and in vivo performance, which are essential for regulatory approval and clinical adoption.

R&D initiatives are also being driven by major implant manufacturers, including Smith+Nephew and Zimmer Biomet, who are investing in SPS to differentiate their product portfolios. These companies are collaborating with plasma equipment suppliers to develop next-generation SPS systems capable of producing nanostructured coatings with controlled porosity and enhanced bioactivity. The goal is to address unmet clinical needs, such as faster bone integration and reduced infection rates.

Looking ahead, the outlook for SPS in biomedical implants is promising, with several pilot clinical studies underway and regulatory submissions expected in the next few years. The convergence of expertise from materials science, biomedical engineering, and manufacturing is expected to yield new coating formulations and process innovations. As these partnerships mature, SPS is poised to become a mainstream technology for advanced orthopedic and dental implants, supported by robust R&D pipelines and industry-wide collaboration.

Future Outlook: Disruptive Trends, Investment Hotspots, and Long-Term Opportunities

Suspension Plasma Spraying (SPS) is rapidly emerging as a disruptive technology in the biomedical implant sector, with 2025 poised to be a pivotal year for its industrial adoption. SPS enables the deposition of ultra-fine, nanostructured coatings, offering superior bioactivity, corrosion resistance, and mechanical properties compared to conventional plasma spraying. This is particularly relevant for orthopedic and dental implants, where enhanced osseointegration and longevity are critical.

Key industry players are intensifying their focus on SPS. Oerlikon, a global leader in surface solutions, has expanded its portfolio to include advanced SPS systems, targeting biomedical applications. Their investments in R&D and partnerships with medical device manufacturers are expected to accelerate the commercialization of SPS-coated implants. Similarly, TST Coatings is actively developing SPS processes for hydroxyapatite and other bioactive coatings, aiming to meet the stringent requirements of next-generation implants.

Investment hotspots are emerging in North America and Europe, where regulatory frameworks and established medical device industries provide fertile ground for SPS innovation. The European Union’s Medical Device Regulation (MDR) is driving demand for coatings that can demonstrate improved safety and performance, further incentivizing the adoption of SPS. In the United States, collaborations between coating technology providers and implant manufacturers are being fostered to fast-track clinical validation and FDA approvals.

Disruptive trends include the integration of SPS with digital manufacturing and robotics, enabling precise, repeatable coating of complex implant geometries. Companies such as GTV Verschleißschutz are advancing automated SPS systems, which are expected to reduce production costs and improve scalability. Additionally, the development of novel suspension feedstocks—such as doped hydroxyapatite, bioglass, and antimicrobial nanoparticles—promises to expand the functional capabilities of SPS coatings, addressing infection control and tissue regeneration.

Looking ahead, long-term opportunities are likely to arise from the convergence of SPS with personalized medicine. The ability to tailor coating composition and microstructure to individual patient needs could revolutionize implant performance and patient outcomes. As SPS technology matures, strategic partnerships between coating specialists, implant manufacturers, and healthcare providers will be crucial for translating laboratory advances into clinical practice.

In summary, 2025 and the following years are set to witness significant investment and innovation in SPS for biomedical implants, with leading companies and regions positioning themselves at the forefront of this transformative trend.

Sources & References

Unlocking the Future of Tech: The Magic of Plasma Treatment!

Watch this video on YouTube

Suspension Plasma Spraying for Biomedical Implants: 2025 Market Surge & Future Innovations

ByQuinn Parker